Sofosbuvir/Ledipasvir Performance in Genotype 3 HCV Infection: Real-Life Evidence of Overcoming a Difficult Patient Subgroup

Andrade Patricia; Macedo Guilherme; Cardoso Helder; Horta e Vale Ana; Rodrigues Susana; Goncalves Regina; Pereira Pedro; Lopes Susana; Santos Lurdes; Pinto Andre; Faustino Ana Sofia; Silva Susana; Soares Jorge; Nuak Joao; Ferreira Alcina; Monteiro Fatima; Araujo Fernando; Sarmento Antonio

首页> 外文期刊>The American Journal of Gastroenterology >Sofosbuvir/Ledipasvir Performance in Genotype 3 HCV Infection: Real-Life Evidence of Overcoming a Difficult Patient Subgroup

【24h】

Sofosbuvir/Ledipasvir Performance in Genotype 3 HCV Infection: Real-Life Evidence of Overcoming a Difficult Patient Subgroup

机译：Sofosbuvir / Ledipasvir在基因型3 HCV感染中的表现：克服困难患者亚组的现实证据

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The American Journal of Gastroenterology 》 |2016年第1期| 共1页
作者
Andrade Patricia; Macedo Guilherme; Cardoso Helder; Horta e Vale Ana; Rodrigues Susana; Goncalves Regina; Pereira Pedro; Lopes Susana; Santos Lurdes; Pinto Andre; Faustino Ana Sofia; Silva Susana; Soares Jorge; Nuak Joao; Ferreira Alcina; Monteiro Fatima; Araujo Fernando; Sarmento Antonio;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. Sofosbuvir/Ledipasvir Performance in Genotype 3 HCV Infection: Real-Life Evidence of Overcoming a Difficult Patient Subgroup [J] . Andrade Patricia, Macedo Guilherme, Cardoso Helder, The American Journal of Gastroenterology . 2016 ,第Suppla1期

机译：Sofosbuvir / Ledipasvir在基因型3 HCV感染中的表现：克服困难患者亚组的现实证据
2. The presence of multiple NS NS 5A RAS RAS s is associated with the outcome of sofosbuvir and ledipasvir therapy in NS NS 5A inhibitor‐na?ve patients with chronic HCV HCV genotype 1b infection in a real‐world cohort [J] . Kozuka R., Hai H., Motoyama H., Journal of viral hepatitis. . 2018 ,第5期

机译：多个NS NS 5A RAS S的存在与NS NS 5A抑制剂-NA'VE患者的Sofosbuvir和Ledipasvir治疗的结果有关，其在真实世界的队列中的慢性HCV HCV基因型1B感染患者
3. Ledipasvir–Sofosbuvir for 8?Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection?±?HIV-1 Co-Infection [J] . Vasily Isakov, Natalia Gankina, Viacheslav Morozov, Clinical drug investigation . 2018 ,第3期

机译：Ledipasvir-sofosbuvir为8？周的非肝硬化患者以前未经治疗的基因型1 hCV感染？±α？HIV-1共感染
4. Influence of hepatitis C virus genotypes and F protein on outcome of HCV infection among injection drug users [C] . Yun Zhang, Jingjing Yang, Haopeng Wang, International symposium on pharmacogenomics and the regulation of drug metabolism enzymes and genes. . 2010

机译：丙型肝炎病毒基因型和F蛋白对注射吸毒者HCV感染结局的影响
5. The impact of pharmacodynamic parameters on prediction of clinical outcome in HIV-1 infected patients and HCV patients with HIV co-infection. [D] . Kim, Tae Eun. 2012

机译：药效学参数对HIV-1感染的患者和HCV合并感染的HCV患者的临床结局预测的影响。
6. Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter Retrospective Study [O] . Bo-Huang Liou, Hsin-Yun Sun, Chia-Jui Yang, 2021

机译：具有Coformulated Ledipasvir和Sofosbuvir的真实世界经验用于HIV阳性患者HCV基因型2感染：多中心回顾性研究
7. Correction to: Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection [O] . Vasily Isakov, Natalia Gankina, Viacheslav Morozov, 2021

机译：校正至：LEDIPASVIR-SOFOSBUVIR在非肝硬化患者中8周，以前未经治疗的基因型1 HCV感染±HIV-1共感染

Sofosbuvir/Ledipasvir Performance in Genotype 3 HCV Infection: Real-Life Evidence of Overcoming a Difficult Patient Subgroup

著录项

相似文献

相关主题

期刊订阅